Key points from article :
Trestle Biotherapeutics to commercialise a suite of stem cell- and 3D bioprinting-based kidney regenerative technologies.
Innovations developed at Harvard’s Wyss Institute, SEAS, and Brigham.
“We’re thrilled with the opportunity to carry their work forward for patients’ benefit,” - Shepherd, the CEO of Trestle.
“We developed a new biomanufacturing method, SWIFT, that enables the fabrication of vascularized kidney tissues. ” - Jennifer Lewis, Wyss professir at Harvard university.
Created 3D kidney-on-chip models for drug screening and disease modelling.
Joint team of Lewis Lab and Brigham generated vascularised kidney organoids with enhanced nephron maturation in vitro.
Combining these approaches, Trestle will work towards...bioengineered kidney tissue with vital kidney functions.
“It will contribute to kidney repair and replacement therapies that patients. We look forward to seeing this technology rapidly advance to the clinic,” - Donald Ingber, Wyss Founding Director.
